| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Human Endogenous Metabolite
H-Tyr(3,5-DiI)-OH targets thyroid hormone biosynthesis pathways as an intermediate. It is a precursor in the synthesis of thyroid hormones T3 and T4. It can also be used as a building block in peptide synthesis for introducing iodinated tyrosine residues. The iodine atoms provide heavy atoms for crystallographic studies and can be used in radioiodination for imaging applications. |
|---|---|
| ln Vitro |
Commercial ergot supplements have been made from amino acids and their derivatives. They affect the release of anabolic hormones, the availability of fuel for activity, the ability to think clearly under pressure, and the prevention of muscular damage brought on by exertion. They are regarded as advantageous synergistic food ingredients [1].
In vitro, H-Tyr(3,5-DiI)-OH has been studied for its role in thyroid hormone biosynthesis and as a precursor to T3 and T4. Amino acid derivatives have been used as ergogenic supplements, affecting the release of anabolic hormones and fuel availability. The compound can be used in cell culture to study iodine metabolism and thyroid hormone synthesis pathways. |
| ln Vivo |
In vivo, H-Tyr(3,5-DiI)-OH is a key intermediate in thyroid hormone biosynthesis. It is formed by iodination of tyrosine and is further coupled to form T3 and T4. The compound has been studied for its role in thyroid function and iodine metabolism. It may be used in animal studies to investigate thyroid hormone synthesis and iodine deficiency disorders.
|
| Enzyme Assay |
In vitro enzyme assays for H-Tyr(3,5-DiI)-OH involve studying its role as a substrate for thyroid peroxidase in thyroid hormone biosynthesis. The compound can be incubated with thyroid peroxidase, iodide, and hydrogen peroxide, and the formation of T3 and T4 is measured by HPLC or radioimmunoassay. Binding studies with thyroid hormone receptors can also be performed using labeled diiodotyrosine derivatives.
|
| Cell Assay |
Cell culture protocols for H-Tyr(3,5-DiI)-OH involve dissolving the compound in sterile water or cell culture medium. Thyroid cell lines (such as FRTL-5) can be treated with the compound to study iodine uptake, organification, and thyroid hormone synthesis. Cells are treated with concentrations ranging from 0.1-100 µM for 24-72 hours. Effects on cell viability, thyroid hormone production, and signaling pathways are assessed.
|
| Animal Protocol |
In vivo animal study protocols for H-Tyr(3,5-DiI)-OH involve administration via oral gavage or injection in saline. Dosing typically ranges from 0.1-10 mg/kg. Studies may assess effects on thyroid hormone levels, iodine metabolism, and thyroid function. Blood and tissue samples (especially thyroid tissue) are collected for analysis of compound distribution, iodine content, and thyroid hormone levels. Standard animal welfare protocols apply.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of H-Tyr(3,5-DiI)-OH are characteristic of iodinated amino acids. The compound has a molecular weight of 432.98 g/mol, formula C₉H₉I₂NO₃, and appears as a white to off-white powder. Refractive index is 1.2° (C=5, 1mol/L HCl). Purity is ≥98%. Storage: powder at -20°C for up to three years or 4°C for up to two years. It is absorbed and distributed to tissues, particularly the thyroid gland. Elimination is via renal excretion.
|
| Toxicity/Toxicokinetics |
Toxicological data for H-Tyr(3,5-DiI)-OH is limited but it is a naturally occurring compound. As an iodinated amino acid, high doses may affect thyroid function. Standard safety precautions should be observed. The compound is not intended for human therapeutic use in its isolated form and is classified for research purposes only. Store at 2-8°C. Proper personal protective equipment should be worn.
|
| References | |
| Additional Infomation |
3,5-Diiodo-L-tyrosine is a diiodotyrosine, specifically an L-tyrosine with iodine substituents at the C-3 and C-5 positions of the benzyl group. It is an intermediate in the synthesis of thyroid hormones. It is a metabolite in both humans and mice. It is a derivative of L-tyrosine, a non-protein L-α-amino acid, and also a diiodotyrosine. It is the conjugate acid of 3,5-diiodo-L-tyrosine (1-). 3,5-Diiodo-L-tyrosine is a metabolite found or produced in Escherichia coli (K12 strain, MG1655 strain). 3,5-Diiodo-L-tyrosine has been reported to be detected in both Homo sapiens and cattle, but the relevant data are unclear. It is a product of the iodination reaction of monoiodotyrosine. In the biosynthesis of thyroid hormones, diiodotyrosine residues combine with other monoiodotyrosine or diiodotyrosine residues to form T4 or T3 thyroid hormones (thyroxine and triiodothyronine).
H-Tyr(3,5-DiI)-OH (CAS#: 300-39-0) is also known as 3,5-Diiodo-L-tyrosine, Diiodotyrosine, Iodogorgoic Acid, and L-Diiodotyrosine. Its molecular formula is C₉H₉I₂NO₃ and molecular weight is 432.98 g/mol. It is a thyroid hormone precursor and iodinated amino acid used in thyroid function research. It has no approved therapeutic indications. |
| Molecular Formula |
C9H9I2NO3
|
|---|---|
| Molecular Weight |
432.9816
|
| Exact Mass |
468.888
|
| CAS # |
300-39-0
|
| PubChem CID |
9305
|
| Appearance |
White to off-white powder
|
| Density |
2.405g/cm3
|
| Boiling Point |
410.5ºC at 760 mmHg
|
| Melting Point |
200 °C (dec.)(lit.)
|
| Flash Point |
202.1ºC
|
| Index of Refraction |
1.2 ° (C=5, 1mol/L HCl)
|
| LogP |
2.127
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
15
|
| Complexity |
227
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
IC1C(=C(C([H])=C(C=1[H])C([H])([H])[C@@]([H])(C(=O)O[H])N([H])[H])I)O[H]
|
| InChi Key |
NYPYHUZRZVSYKL-ZETCQYMHSA-N
|
| InChi Code |
InChI=1S/C9H9I2NO3/c10-5-1-4(2-6(11)8(5)13)3-7(12)9(14)15/h1-2,7,13H,3,12H2,(H,14,15)/t7-/m0/s1
|
| Chemical Name |
(2S)-2-amino-3-(4-hydroxy-3,5-diiodophenyl)propanoic acid
|
| Synonyms |
3,5-Diiodo-L-tyrosine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~115.48 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3096 mL | 11.5479 mL | 23.0958 mL | |
| 5 mM | 0.4619 mL | 2.3096 mL | 4.6192 mL | |
| 10 mM | 0.2310 mL | 1.1548 mL | 2.3096 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
